Krebs Bankrott

Cancer Costs, Exposed

Breaking News
Patient Debt

Wegovy lowers BMI in young children

By Wren Hollings November 17, 2026
Wegovy lowers BMI in young children - wegovy bmi
The trial enrolled 167 children with an average age of 10.

A recent trial published in The New England Journal of Medicine found that children ages 6 to 11 with obesity who took weekly semaglutide, the drug sold as Wegovy, lowered their body mass index (BMI) by an average of 13.5% over 68 weeks. In contrast, BMI rose by 2.7% among children on placebo.

The trial, known as STEP Young, enrolled 167 children, with 112 assigned to semaglutide and 55 to placebo. The average age of the children was 10, and 59% were girls. More than 85% of the children had class II or III obesity at the start of the trial.

Results and Side Effects

The trial found that 38.4% of children on semaglutide were no longer classified as having obesity at 68 weeks, compared with 2.1% on placebo. About three in four children on semaglutide lowered their BMI by at least 10%. However, the trial also showed that 70% of children on semaglutide experienced vomiting, compared with 29% on placebo.

Other side effects reported by children on semaglutide included diarrhea and nausea, which affected 62% and 58% of children, respectively. Despite these side effects, few children stopped taking the drug due to adverse events, with 4% on semaglutide and 2% on placebo discontinuing treatment.

The trial also investigated the effect of semaglutide on growth and puberty in children. According to Dr. Antje Körner, a trial investigator, researchers saw no effects on puberty, pubertal development, or bone mineral density. Height was slightly greater in the semaglutide group, but the difference was not significant.

In terms of other health markers, the trial found that semaglutide improved several measures, including waist size, triglycerides, blood pressure, and a marker of inflammation. Lead author Dr. Ania Jastreboff noted that treatment “was accompanied by improvements in multiple cardiometabolic measures.”

Implications and Future Directions

The results of the STEP Young trial have significant implications for the treatment of obesity in children. While Wegovy is currently approved only for people 12 and older, the trial suggests that it may be effective in younger children as well. However, the high rate of side effects, particularly vomiting, is a concern that needs to be addressed.

Dr. Daniel Hsia, a division chief of pediatric endocrinology at Emory University, noted that the results of the trial could support a shift in the treatment of obesity, moving away from watchful waiting and towards earlier intervention. He also emphasized that key questions remain, including which children benefit most from treatment and what happens beyond two years.

The World Health Organization has issued guidance on the use of obesity medication in children, recommending that approved medicines may be considered for those 10 to 19 only after a supervised lifestyle program has not worked. The American Academy of Pediatrics has also issued guidelines, which recommend offering weight-loss medication to adolescents 12 and older.

Novo Nordisk, the manufacturer of Wegovy, has not announced when it might seek FDA approval for younger children. The company’s announcement of the trial results highlighted the 17.4% reduction in BMI seen in children who stayed on treatment, but this figure should be interpreted cautiously, according to some experts.

Children on semaglutide saw their BMI fall by 9.4% at two years, compared with a 8.4% increase in the placebo group.

Parents can ask the pediatrician about qualifying for a pediatric weight management program and monitoring growth and nutrition. Children already on a GLP-1 drug should not stop without medical advice. Vomiting that will not stop, severe stomach pain, or signs of dehydration need prompt medical care. The next milestones are longer off-treatment data and any FDA filing.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2026 Krebs Bankrott. All rights reserved.